197 related articles for article (PubMed ID: 33255857)
1. Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.
Aguirre-Ruiz P; Ariceta B; Viguria MC; Zudaire MT; Blasco-Iturri Z; Arnedo P; Aguilera-Diaz A; Jauregui A; Mañú A; Prosper F; Mateos MC; Fernández-Mercado M; Larráyoz MJ; Redondo M; Calasanz MJ; Vázquez I; Bandrés E
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33255857
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
4. Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation: Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR.
Zhang A; Macecevic S; Thomas D; Allen J; Mandley S; Kawczak P; Jurcago R; Tyler J; Casey H; Bosler D; Sobecks R; Hamilton B; Sauter C; Mineishi S; Claxton D; Shike H
J Mol Diagn; 2024 Apr; 26(4):233-244. PubMed ID: 38307253
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods.
Brow D; Shike H; Kendrick J; Pettersson L; Mineishi S; Claxton DF; Wirk B; Cioccio J; Greiner RJ; Viswanatha D; Kharfan-Dabaja MA; Li Z; Tyler J; Elrefaei M
Hum Immunol; 2024 May; 85(3):110794. PubMed ID: 38553384
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic Syndrome.
Lee JM; Kim YJ; Park SS; Han E; Kim M; Kim Y
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31795155
[TBL] [Abstract][Full Text] [Related]
7. Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies.
Liacini A; Tripathi G; McCollick A; Gravante C; Abdelmessieh P; Shestovska Y; Mathew L; Geier S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511573
[TBL] [Abstract][Full Text] [Related]
8. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
9. Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation.
Kakodkar P; Zhao Y; Pan H; Wu F; Pearce T; Webster D; Elemary M; Sabry W; Kwan L; Pelzer L; Bosch M; Sherwood KR; Lan J; Tran J; Liwski R; Keown P; Mostafa A
Front Genet; 2023; 14():1282947. PubMed ID: 37937195
[TBL] [Abstract][Full Text] [Related]
10. The mythological chimera and new era of relapse prediction post-transplant.
Ciurea SO; Kothari A; Sana S; Al Malki MM
Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.
Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J
Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973
[TBL] [Abstract][Full Text] [Related]
12. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
[TBL] [Abstract][Full Text] [Related]
13. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms.
Puzo CJ; Tormey CA; Rinder HM; Siddon AJ
Transplant Cell Ther; 2023 Jul; 29(7):459.e1-459.e4. PubMed ID: 37062510
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation.
Waterhouse M; Pennisi S; Pfeifer D; Scherer F; Zeiser R; Duyster J; Bertz H; Finke J; Duque-Afonso J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884368
[TBL] [Abstract][Full Text] [Related]
16. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
17. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.
Cheng S; Inghirami G; Cheng S; Tam W
J Hematol Oncol; 2018 Aug; 11(1):105. PubMed ID: 30134947
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.
Kotrova M; van der Velden VHJ; van Dongen JJM; Formankova R; Sedlacek P; Brüggemann M; Zuna J; Stary J; Trka J; Fronkova E
Bone Marrow Transplant; 2017 Jul; 52(7):962-968. PubMed ID: 28244980
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
20. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
